Frost & Sullivan report: Global diabetes market will increase

LONDON Increased knowledge of the pathology of diabetes will lead to improved drugs to treat the disease, according to a new report by market research firm Frost & Sullivan.

The report, Global Diabetes Market, found that the market earned revenues of $27 billion last year and is estimated to reach $44.7 billion by 2015.

“Improved therapies and innovative drug delivery techniques are anticipated to revolutionize the global diabetes market by 2015,” Frost & Sullivan program leader Sylvia Miriyam Findlay said in a statement. “As health care moves towards preventive medicine, the search for a cure for diabetes looks promising.”

The report noted that the market landscape is changing because of the introduction of new drug classes, such as GLP-1 analogs, such as Byetta (exenatide), made by Eli Lilly & Co., Amylin Pharmaceuticals and Alkermes.